2014—2016年解放军第302医院住院药房抗乙型肝炎病毒核苷(酸)类似物应用分析
目的:了解解放军第302医院(以下简称'我院')住院药房抗乙型肝炎病毒(hepatitis B virus,HBV)核苷(酸)类似物的使用情况及趋势,为临床合理用药提供参考。方法:采用回顾性分析法,通过住院药房信息管理系统,提取2014—2016年我院抗HBV核苷(酸)类似物的使用量、销售金额,对用药频度及限定日费用等进行统计分析。结果:2014—2016年我院抗HBV核苷(酸)类似物的使用量、销售金额总体呈逐年递增趋势,2015年其销售金额增长率高达11.23%(2014年为342.99万元,2015年为363.71万元)。恩替卡韦和替诺福韦的使用量均呈逐...
Saved in:
| Published in | 中国医院用药评价与分析 Vol. 17; no. 9; pp. 1168 - 1170 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
解放军第302医院药学部,北京,100039
2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1672-2124 |
| DOI | 10.14009/j.issn.1672-2124.2017.09.006 |
Cover
| Abstract | 目的:了解解放军第302医院(以下简称'我院')住院药房抗乙型肝炎病毒(hepatitis B virus,HBV)核苷(酸)类似物的使用情况及趋势,为临床合理用药提供参考。方法:采用回顾性分析法,通过住院药房信息管理系统,提取2014—2016年我院抗HBV核苷(酸)类似物的使用量、销售金额,对用药频度及限定日费用等进行统计分析。结果:2014—2016年我院抗HBV核苷(酸)类似物的使用量、销售金额总体呈逐年递增趋势,2015年其销售金额增长率高达11.23%(2014年为342.99万元,2015年为363.71万元)。恩替卡韦和替诺福韦的使用量均呈逐年递增趋势,而拉米夫定、阿德福韦酯和替比夫定的使用量有所降低;3年来,恩替卡韦和替比夫定的药品销售金额排序/用药频度排序的比值均为1,表明其用药人数与销售金额的同步性良好。结论:核苷(酸)类似物已经成为抗HBV的首选药物,临床上更倾向于选择高效低耐药率的阿德福韦酯、恩替卡韦和替诺福韦。临床医师应进一步规范应用核苷(酸)类似物,根据患者个体情况制订合理的治疗方案,降低耐药率。 |
|---|---|
| AbstractList | 目的:了解解放军第302医院(以下简称'我院')住院药房抗乙型肝炎病毒(hepatitis B virus,HBV)核苷(酸)类似物的使用情况及趋势,为临床合理用药提供参考。方法:采用回顾性分析法,通过住院药房信息管理系统,提取2014—2016年我院抗HBV核苷(酸)类似物的使用量、销售金额,对用药频度及限定日费用等进行统计分析。结果:2014—2016年我院抗HBV核苷(酸)类似物的使用量、销售金额总体呈逐年递增趋势,2015年其销售金额增长率高达11.23%(2014年为342.99万元,2015年为363.71万元)。恩替卡韦和替诺福韦的使用量均呈逐年递增趋势,而拉米夫定、阿德福韦酯和替比夫定的使用量有所降低;3年来,恩替卡韦和替比夫定的药品销售金额排序/用药频度排序的比值均为1,表明其用药人数与销售金额的同步性良好。结论:核苷(酸)类似物已经成为抗HBV的首选药物,临床上更倾向于选择高效低耐药率的阿德福韦酯、恩替卡韦和替诺福韦。临床医师应进一步规范应用核苷(酸)类似物,根据患者个体情况制订合理的治疗方案,降低耐药率。 R978.7; 目的:了解解放军第302医院(以下简称"我院")住院药房抗乙型肝炎病毒(hepatitis B virus,HBV)核苷(酸)类似物的使用情况及趋势,为临床合理用药提供参考.方法:采用回顾性分析法,通过住院药房信息管理系统,提取2014—2016年我院抗HBV核苷(酸)类似物的使用量、销售金额,对用药频度及限定日费用等进行统计分析.结果:2014—2016年我院抗HBV核苷(酸)类似物的使用量、销售金额总体呈逐年递增趋势,2015年其销售金额增长率高达11.23％(2014年为342.99万元,2015年为363.71万元).恩替卡韦和替诺福韦的使用量均呈逐年递增趋势,而拉米夫定、阿德福韦酯和替比夫定的使用量有所降低;3年来,恩替卡韦和替比夫定的药品销售金额排序/用药频度排序的比值均为1,表明其用药人数与销售金额的同步性良好.结论:核苷(酸)类似物已经成为抗HBV的首选药物,临床上更倾向于选择高效低耐药率的阿德福韦酯、恩替卡韦和替诺福韦.临床医师应进一步规范应用核苷(酸)类似物,根据患者个体情况制订合理的治疗方案,降低耐药率. |
| Abstract_FL | OBJECTIVE:To investigate the application status and trend of anti-HBV nucleoside( acid) analogues based on the clinical treatment of hepatitis B in 302 Hospital of People' s Liberation Army, so as to provide reference for clinical rational drug application. METHODS: Retrospective analysis method was adopted, the consumption amount, comsumption sum, defined daily dose( DDDs) and defined daily cost( DDC) of anti-HBV nucleoside( acid) analogues based on the clinical treatment of hepatitis B extracted from in-patient pharmacy information system during 2014-2016 were statistically analyzed. RESULTS: The consumption amount and consumption sum of anti-HBV nucleoside( acid) analogues during 2014-2016 were in an increasing trend year to year, and the increasing rate was up to 11. 23％ in 2015 ( 3. 4299 million yuan in 2014 , 3. 6371 million yuan in 2015 ) . The consumption amount of entecavir and tenofovir was in an increasing trend, yet the clinical application of lamivudine, adefovir dipivoxil and telbivudine decreased year to year. For three years, the ratio of consumption sum ranking/medication frequence ranking was 1, which showed good synchronization between the number of patients and consumption sum. CONCLUSIONS:Nucleoside( acid) analogues has become the preferred drug for anti-HBV, the clinic are more likely to choose effective and low-resistance drugs as entecavir, adefovir dipivoxil and tenofovir in clinical treatment. The clinicians should regulate and rational application of anti-HBV nucleoside ( acid ) analogues, formulate rational treatment regimen according to the individual conditions and reduce the drug resistance. |
| Author | 王欢 谢进 何惠芳 刘丽萍 杨飞飞 牛红娟 赵艳玲 |
| AuthorAffiliation | 解放军第302医院药学部 |
| AuthorAffiliation_xml | – name: 解放军第302医院药学部,北京,100039 |
| Author_FL | XIE Jin HE Huifang WANG Huan ZHAO Yanling NIU Hongjuan LIU Liping YANG Feifei |
| Author_FL_xml | – sequence: 1 fullname: WANG Huan – sequence: 2 fullname: XIE Jin – sequence: 3 fullname: HE Huifang – sequence: 4 fullname: LIU Liping – sequence: 5 fullname: YANG Feifei – sequence: 6 fullname: NIU Hongjuan – sequence: 7 fullname: ZHAO Yanling |
| Author_xml | – sequence: 1 fullname: 王欢 谢进 何惠芳 刘丽萍 杨飞飞 牛红娟 赵艳玲 |
| BookMark | eNo9UMlKA0EQ7UME4_IZgoIZq5eZ6T6KuEHAS-6hZ4sJOtEMovEkgsFdkQERUUQPKgSCIBg16r9IZvEvbFGsgnpF8V5V8fpQxq_6LkJDGDTMAMRYRSsHga9hwyQ5ggnTCGBTA6EBGBmU_Z_3osEgKFtAdBMIoSyLHMVknxuhAiN6fkxvb-LwPWqcJ80mBRLtv36dXXffjlRND1rx9ke8e9p9Posu99LNi2TzMDndilsn8VU73Xsa_tpqjyQPr91OJ9m5j17CJLyLthvx5fEA6vHkQuAO_mE_KkxNFiZmcvm56dmJ8XzO5tjIWQY2CRO21InrcUIUWhS4bbsAHnOIK7irXrc8S1CBJUhpmY5jSQcoox7htB-N_q5dlb4n_VKxUl2p-epgcb1UV7FUqXtrP86AUL4oOv2l2_NVv7RcVoKlWnlR1upFLlSCCTowzoSuM66bquM6o98NIYs5 |
| ClassificationCodes | R978.7 |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.14009/j.issn.1672-2124.2017.09.006 |
| DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitle_FL | Analysis on Application of Anti-HBV Nucleoside ( acid ) Analogues Based on the Clinical Treatment of Hepatitis B in 302 Hospital of People' s Liberation Army During 2014-2016 |
| EndPage | 1170 |
| ExternalDocumentID | zgyyyypjyfx201709006 89898070504849554857484854 |
| GrantInformation_xml | – fundername: 军队十二五面上课题; 国家重大新药创制专项 funderid: (CWS11C164); (2015ZX09J15102-004) |
| GroupedDBID | 2RA 92L ALMA_UNASSIGNED_HOLDINGS CDYEO CQIGP ~WA 2B. 4A8 92I 93N ABDBF ACUHS EOJEC OBODZ PSX TCJ TUS |
| ID | FETCH-LOGICAL-c816-b617249ca52ef822a52b308cce00f4d2e98eb02bfb9391a0aab7ddbad0343f283 |
| ISSN | 1672-2124 |
| IngestDate | Thu May 29 04:11:27 EDT 2025 Wed Feb 14 09:57:45 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 9 |
| Keywords | 用药分析 Anti-HBV nucleoside( acid) analogues Analysis of drug application 核苷(酸)类似物 乙型肝炎病毒 Hepatitis B |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c816-b617249ca52ef822a52b308cce00f4d2e98eb02bfb9391a0aab7ddbad0343f283 |
| Notes | WANG Huan;XIE Jin;HE Huifang;LIU Liping;YANG Feifei;NIU Hongjuan;ZHAO Yanling;Dept. of Pharmacy,302 Hospital of People’s Liberation Army 11-4975/R |
| PageCount | 3 |
| ParticipantIDs | wanfang_journals_zgyyyypjyfx201709006 chongqing_primary_89898070504849554857484854 |
| PublicationCentury | 2000 |
| PublicationDate | 2017 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – year: 2017 text: 2017 |
| PublicationDecade | 2010 |
| PublicationTitle | 中国医院用药评价与分析 |
| PublicationTitleAlternate | Evaluation and Analysis of Drug-Use in Hospitals of China |
| PublicationTitle_FL | Evaluation and Analysis of Drug-Use in Hospitals of China |
| PublicationYear | 2017 |
| Publisher | 解放军第302医院药学部,北京,100039 |
| Publisher_xml | – name: 解放军第302医院药学部,北京,100039 |
| SSID | ssib025702234 ssib017477209 ssib001103637 ssib051368574 ssib000405437 ssib001215202 ssib036441963 ssib006563103 ssib057928707 |
| Score | 2.0608442 |
| Snippet | 目的:了解解放军第302医院(以下简称'我院')住院药房抗乙型肝炎病毒(hepatitis B... R978.7; 目的:了解解放军第302医院(以下简称"我院")住院药房抗乙型肝炎病毒(hepatitis B... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 1168 |
| SubjectTerms | 乙型肝炎病毒;核苷(酸)类似物;用药分析 |
| Title | 2014—2016年解放军第302医院住院药房抗乙型肝炎病毒核苷(酸)类似物应用分析 |
| URI | http://lib.cqvip.com/qk/86765X/201709/89898070504849554857484854.html https://d.wanfangdata.com.cn/periodical/zgyyyypjyfx201709006 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1daxNB8CwpiC-iqPhZ-uCCgql3e7t3u4-3yYUi6FML9Snc5XItPqRVW7B9kkJLtX4hgVLEIvqgQqEIgq2t-l-kSdp_4czeJTklStVwbHbn5mZ3Zu52Z5LbGcO4KFlUpSaP81YUcQyqzfNSsDDPnICGFQo2s4n7na_fcIZH2bUxPtaXO5R5a2lmOhyqzPXcV_IvWgUY6BV3yf6FZjtEAQB10C-UoGEoD6RjWFZZ-20FRtFB9jlRkiiACuK5xLOJ78A5onw8JaCuiA_wAhy2STWwQBQAJZGSeAAB5CIRpQxEEFEkXglJCUFUUvGIdDWyRgM60idCaWRKZBF7gYrwsQKYguNVQERSXTGJEhpZEeWClYvdAQ4AqcRLlKVHBfQLeCA1GIzuSHnIEZJlxBOaBYGsIac-SdKCtu1tTQFEUdQjVMhaD5Y7pDqcCiwF05frESZ0hP-b7uCW1WNMZOBoAdPuGZCamYoSxCdV94yWttTCETaKBcfgEWV3UXSHUqRDQA6gacJIs7_YJFtT9dP1H7rv8M9RZJ6jtWKjaGghxU-17iEdWrD0tuvMyua4NA92Cvtp6XMzj7jMrGOWlSQ7Sm0iTE_Uc72FFUDqBRf7GOr0ga9Mujp-sPlLnHNtOc2Nz8Jn6tZsfA8RTamD5vdT17V4zuj3VFGVMj4HeBUZGxrsVdvJtjEzcyaGHTgomDuv3QaPGxzIbow6Gx0A2Y05xy1MwdD1gbgr8b9_nZSpzc5hg7SZvfonVjE-y8Rkbfw2WJ16E2AtDmrjGXt15JhxNHU0B71k1jhu9M1NnDAinDG-36_jXNHY-rj39k2z_rWx-KK1vg53ROPR9v7q690vT6Hce7zRXPrWfLiyu7XaWFvem3_Zmn_SWllobjxvvtrcW_50aX9h83Lrw_buzk7rwfvG53qr_q6xtNhce3bSGCn5I4XhfJpnJV8RlpMP0YlhshJwWo3BX4Dv0DZFpVI1zZhFtCpFNTRpGIfSllZgBkHoRlEYRKbN7Bjck1NGrjZZq542Bp1QBjEXLnPAD-MxZgt1JIWWkOD4cfuMcaUjoPJUEk6njAlsBVgeHIwJJsG9QXUIKNkZg6QyLKez7t1yr3vn7AHxzhlHsJ78gnreyE3fmaleAJ9iOhxI77oB8Kpvjv4AE47iPw |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=2014%E2%80%942016%E5%B9%B4%E8%A7%A3%E6%94%BE%E5%86%9B%E7%AC%AC302%E5%8C%BB%E9%99%A2%E4%BD%8F%E9%99%A2%E8%8D%AF%E6%88%BF%E6%8A%97%E4%B9%99%E5%9E%8B%E8%82%9D%E7%82%8E%E7%97%85%E6%AF%92%E6%A0%B8%E8%8B%B7%28%E9%85%B8%29%E7%B1%BB%E4%BC%BC%E7%89%A9%E5%BA%94%E7%94%A8%E5%88%86%E6%9E%90&rft.jtitle=%E4%B8%AD%E5%9B%BD%E5%8C%BB%E9%99%A2%E7%94%A8%E8%8D%AF%E8%AF%84%E4%BB%B7%E4%B8%8E%E5%88%86%E6%9E%90&rft.au=%E7%8E%8B%E6%AC%A2&rft.au=%E8%B0%A2%E8%BF%9B&rft.au=%E4%BD%95%E6%83%A0%E8%8A%B3&rft.au=%E5%88%98%E4%B8%BD%E8%90%8D&rft.date=2017&rft.pub=%E8%A7%A3%E6%94%BE%E5%86%9B%E7%AC%AC302%E5%8C%BB%E9%99%A2%E8%8D%AF%E5%AD%A6%E9%83%A8%2C%E5%8C%97%E4%BA%AC%2C100039&rft.issn=1672-2124&rft.volume=17&rft.issue=9&rft.spage=1168&rft.epage=1170&rft_id=info:doi/10.14009%2Fj.issn.1672-2124.2017.09.006&rft.externalDocID=zgyyyypjyfx201709006 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F86765X%2F86765X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgyyyypjyfx%2Fzgyyyypjyfx.jpg |